TLP
VKTX icon

Tri Locum Partners’s Viking Therapeutics VKTX Stock Holding History

Tri Locum Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-200,000
Closed -$3.33M – 80
2023
Q1 		$3.33M Buy
+200,000
New +$2.07M 1.01% 30

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Tri Locum Partners's VKTX Position: Q2 2023 in Review

Tri Locum Partners sold out of Viking Therapeutics (VKTX) in Q2 2023, closing a stake of 200,000 shares — an estimated $3.33M sold.

Tri Locum Partners first reported a position in VKTX in Q1 2023 and held it in 1 quarter. The position peaked at $3.33M in Q1 2023. 193 funds tracked by Wall St. Rank hold VKTX as of Q2 2023.

  • Tri Locum Partners reported no remaining Viking Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Tri Locum Partners sold 200,000 Viking Therapeutics shares in Q2 2023, an estimated $3.33M.
  • Tri Locum Partners first reported a position in Viking Therapeutics in Q1 2023 and held it in 1 quarter.
  • Tri Locum Partners's Viking Therapeutics position peaked at $3.33M in Q1 2023.
  • 193 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2023.

Based on Tri Locum Partners's 13F filing for Q2 2023, filed 14 Aug 2023.